| Literature DB >> 35325447 |
M Žarković1,2, P Perros3, J Ćirić4,5, B Beleslin4,5, M Stojanović4,5, M Stojković4,5, M Miletić4,5, T Janić5.
Abstract
PURPOSE: The aim of this study was to assess the impact of repurposing health care facilities in response to COVID-19 on the access of patients with thyroid disease to health care.Entities:
Keywords: COVID-19; Health care; Pandemic; Serbia; Thyroid
Mesh:
Year: 2022 PMID: 35325447 PMCID: PMC8944403 DOI: 10.1007/s40618-022-01787-6
Source DB: PubMed Journal: J Endocrinol Invest ISSN: 0391-4097 Impact factor: 5.467
Characteristics of the respondents
| All ( | |
|---|---|
| Answered survey—count (%) | |
| For her/himself | 191 (92.7) |
| For child | 15 (7.3) |
| Sex—count (%) | |
| Male | 13 (6.3) |
| Female | 193 (93.7) |
| Age | |
| Mean (95%CI) | 47.1 (45.4, 48.9) |
| Education level | |
| Elementary school | 11 (5.4) |
| High school | 91 (44.6) |
| Vocational degree | 37 (18.1) |
| University degree | 65 (31.9) |
| Diagnosis—count (%) | |
| Hypothyroidism | 97 (47.7) |
| Hyperthyroidism | 28 (14.0) |
| Hashimoto thyroiditis | 101 (52.3) |
| Goitre | 36 (18.1) |
| Thyroid cancer | 11 (5.2) |
| Graves’ orbitopathy | 5 (2.4) |
| How long have you known about your diagnosis (years) | |
| Mean (95%CI) | 8.0 (6.9, 9.1) |
| | 190 |
| For how many years have you been treated (so far) | |
| Mean (95%CI) | 6.6 (5.6, 7.6) |
| | 178 |
| Therapy—count (%) | |
| Drugs | 166 (81.0) |
| Surgery | 32 (15.5) |
| Radioactive iodine | 10 (4.9) |
| Supplements | 8 (3.9) |
| Follow-up only | 6 (2.9) |
| Glucocorticoids | 2(1.0) |
Respondents’ diagnosis and length of treatment
| Hashimoto thyroiditis | Hyperthyroidism | Hypothyroidism | Thyroid cancer | Goitre | Total | |
|---|---|---|---|---|---|---|
| Diagnosis known (years) | ||||||
| 99 (38.1) | 26 (10) | 91 (35.0) | 10 (3.8) | 34 (13.1) | 260 | |
| Median (Q1, Q3) | 5.0 (2.0, 10.5) | 2.5 (1.0, 5.0) | 6.0 (3.0, 13.8) | 7.0 (4.2, 10.8) | 5.0 (1.6, 14.2) | 5.0 (2.0, 12.0) |
| Range | 0.1–43.0 | 0.3–26.0 | 0.2–35.0 | 1.0–35.0 | 0.0–30.0 | 0.0–43.0 |
| Treated for (years) | ||||||
| 94 (38.1) | 26 (10.5) | 88 (35.6) | 10 (4.0) | 29 (11.7) | 247 | |
| Median (Q1, Q3) | 4.0 (1.6, 10.0) | 2.0 (1.0, 4.0) | 5.0 (2.0, 12.0) | 6.5 (3.2, 8.0) | 4.0 (1.0, 10.0) | 4.0 (1.5, 10.0) |
| Range | 0.0–27.0 | 0.1–11.0 | 0.1–28.0 | 1.0–21.0 | 0.5–25.0 | 0.0–28.0 |
Ease of access to physicians by speciality
| Speciality | Easy | With difficulty | Could not access | Did not need |
|---|---|---|---|---|
| General practice | 58 (30.9) [36.9] | 74 (39.4) [47.1] | 25 (13.3) [15.9] | 31 (16.5) |
| Endocrinology | 35 (18.6) [21.7] | 43 (22.9) [28.0] | 83 (44.1) [51.6] | 27 (14.4) |
| Nuclear medicine | 10 (5.3) [28.6] | 8 (4.3) [22.9] | 17 (9.0) [48.6] | 153 (81.4) |
| Thyroid surgery | 4 (2.1) [13.3] | 12 (6.4) [40] | 14 (7.4) [46.7] | 158 (84.0) |
Data are presented as count (% all patients) [% of patients who needed access]. The total number of responses was 188
Fig. 1Influence of pandemics in the public health care access
Fig. 2Influence of pandemic on thyroid disease management
Fig. 3Level of concern for health due to pandemics. The level of concern for the responders’ thyroid health caused by pandemics is expressed from 0—not concerned at all, to 10—panicked. The data are presented by a histogram. The shaded horizontal bar represents interquartile range and the short bold vertical line on this bar represents the median
Fig. 4Sources of information on the effect of the pandemic on thyroid disease